about
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza InfectionsInfluenza prevention and treatment in transplant recipients and immunocompromised hostsAssays for monitoring susceptibility of influenza viruses to neuraminidase inhibitorsNeuraminidase inhibitors for influenza B virus infection: efficacy and resistanceSafety and efficacy of peramivir for influenza treatmentCarrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir AnalogueThe anti-influenza virus effect of Phellinus igniarius extract.Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.Recent progress and challenges in the discovery of new neuraminidase inhibitors.Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) virusesTherapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.Influenza vaccines and vaccinations in Poland - past, present and future.Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.Detection and management of antiviral resistance for influenza viruses.Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.Autodisplay of an archaeal γ-lactamase on the cell surface of Escherichia coli using Xcc_Est as an anchoring scaffold and its application for preparation of the enantiopure antiviral drug intermediate (-) vince lactam.Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
P2860
Q26749578-6E494682-0D78-4DAF-9E6C-7CEB6352762FQ27011595-8C892C07-6CAF-473D-84A7-E340FFAD7A9AQ27013442-5880841A-3CF8-4041-B0B4-E0E73F3F428EQ27021579-37EB7EC0-78D9-4A12-9DF4-96177950080AQ27027408-99BB4F42-3F14-4E1D-9409-9ACB5ECDD68EQ28833485-E22834D8-751A-47E2-9A71-70BE80C33656Q30355058-C68786E0-3140-4E04-AEFD-4842944FA7D3Q30364319-10286ADE-78C9-4EE8-BDFC-5ECCC98CAA29Q30426630-0BD21A25-463F-4A7A-8C0B-174596B4616CQ34292717-18281243-7C71-43AC-A121-FBE2E08A03A6Q35168895-30BD502C-31D3-4DF2-8C00-F4A41ACAC604Q36171626-9B9B71C6-05C0-48E9-97A5-44F1A89E5D0AQ36576966-8F0AD1C6-B782-4D0E-87A5-1C4B750153A9Q36785817-A6E98168-DB64-462D-A71A-06AA8491EDC3Q37263328-2CDBBA2D-F68E-4573-8871-AD1B6A8FE8AAQ38161553-0E2D2F9F-E9DE-411F-8324-14CB4E0029B2Q39508037-F4C1F465-A798-45E0-8491-E6E9729A0CB9Q41854401-47DF43E1-FA32-492E-BA85-C6564F00272AQ42199847-85F91241-D136-4330-A8EF-5F40CDE213BCQ43021420-60234340-FAF0-4FD3-BC71-D5E779D9111AQ45947329-7F08DE52-0517-46DC-A607-9AB6B3392EA7
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Peramivir for the treatment of influenza.
@ast
Peramivir for the treatment of influenza.
@en
type
label
Peramivir for the treatment of influenza.
@ast
Peramivir for the treatment of influenza.
@en
prefLabel
Peramivir for the treatment of influenza.
@ast
Peramivir for the treatment of influenza.
@en
P2860
P356
P1476
Peramivir for the treatment of influenza.
@en
P2093
Leigh A Peek
P2860
P304
P356
10.1586/ERI.11.174
P577
2012-02-01T00:00:00Z